Immunome Inc. Announces Inducement Grants with Stock Options for New Employees Under 2024 Plan
Reuters
Aug 02
<a href="https://laohu8.com/S/IMNM">Immunome Inc.</a> Announces Inducement Grants with Stock Options for New Employees Under 2024 Plan
Immunome Inc., a biotechnology company specializing in targeted cancer therapies, has announced the granting of inducement awards under its 2024 Inducement Plan. On August 1, 2025, the company's Compensation Committee approved non-statutory stock options for five new employees, allowing them to purchase a total of 39,000 shares of common stock. The exercise price for these stock options is set at $10.59 per share, reflecting the company's closing sales price on the grant date. The options will vest over a period of four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining shares vesting monthly over the next 36 months. These inducement grants are offered in line with Nasdaq Listing Rule 5635(c)(4).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801450022) on August 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.